Getty Images A new clinical trial shows the immunotherapy drug dostarlimab could eliminate the need for surgery and chemotherapy in certain cancers. The results are a medical breakthrough since ...

Dostarlimab treatment led to complete clinical responses in 82% of patients with dMMR tumors, avoiding surgery for most. Recurrence-free survival at two years was 92%, with a median follow-up of ...

Dostarlimab offers hope in cancer treatment. Study shows tumour shrinkage in patients with mismatch repair defect. Some rectal cancer patients saw complete tumour disappearance. Maureen Sideris ...

The trial sponsored by GSK Plc (NYSE:GSK) assessed the belrestotug + dostarlimab doublet in previously untreated, unresectable, locally advanced, or metastatic PD-L1 high non-small cell lung ...

Most study participants were able to avoid operations after taking dostarlimab. A new study in the New England Journal of Medicine suggests that some people with early stage cancers may be able to ...

The decision came after the GALAXIES Lung-201 study, which evaluated belrestotug in combination with dostarlimab for the treatment of PD-L1 high non-small cell lung cancer (NSCLC), failed to meet ...

dostarlimab monotherapy in PD-L1 positive head and neck squamous cell carcinoma. Based on these results, iTeos and GSK have decided to terminate the belrestotug development program and end the ...

Six months of treatment with dostarlimab led to nonoperative management in 80% of patients with stages I-III MMRd rectal and non-rectal tumors. And in all patients who had a clinical complete ...